Iran Diabetes Care Drugs And Devices Market: Market Size & Forecast 2026

The global diabetes care drugs and devices market covers the full spectrum of products and technologies used to diagnose, monitor, and treat diabetes mellitus, including insulin, oral anti-diabetic drugs, CGM systems, insulin pumps, and traditional glucose meters. Valued at approximately $97.89 billion in 2025 and growing at a 9.7% CAGR, the market represents one of the fastest-growing segments in the global pharmaceutical and medical technology industries. The market reflects the combined value of therapeutic drugs and diagnostic-monitoring devices, with projections placing the combined market well over $400 billion by the early 2030s when broader diabetes ecosystem spending is included.

• •The 2025 market valuation of $97.89 billion encompasses both pharmaceutical and device segments, with the combined diabetes ecosystem projected to exceed $400 billion by 2033
• •The devices segment alone ranges from approximately $39.82 billion to $61.22 billion in 2025 depending on reporting scope, with CGM devices representing the fastest-growing subcategory within devices
• •Drug spending is led by insulin, which remains the dominant therapeutic class, alongside rapidly growing GLP-1 receptor agonist therapies that are reshaping treatment paradigms globally

Rising global diabetes prevalence is the primary catalyst for market expansion, with the International Diabetes Federation estimating over 460 million adults living with diabetes worldwide, a figure projected to reach 700 million by 2045. Aging demographics, increasing urbanization, sedentary lifestyles, and growing obesity rates across both developed and developing economies are expanding the patient population requiring ongoing diabetes management products. Improved diagnostic screening, expanded insurance coverage in emerging markets, and the growing trend of early-stage intervention have collectively driven higher diagnosis rates and treatment adoption.

• •Type 2 diabetes accounts for roughly 90% of all diabetes cases globally, and its association with modifiable lifestyle factors ensures a growing incidence trajectory as obesity rates rise
• •The GLP-1 receptor agonist drug class has emerged as a particularly powerful growth driver due to superior efficacy, cardiovascular benefits, and expanding use in obesity management
• •Improved healthcare access in emerging economies, rising per capita spending on chronic disease management, and expanded government screening programs in Asia-Pacific and Latin America are accelerating market expansion beyond traditional Western markets

The diabetes care market is broadly segmented into drugs, dominated by insulin and insulin analogues, GLP-1 agonists, DPP-4 inhibitors, and SGLT2 inhibitors, and devices including CGM systems, insulin pumps, blood glucose meters, and insulin pens. Regionally, North America commands the largest share at roughly 35-40%, driven by high diabetes prevalence, advanced healthcare infrastructure, favorable reimbursement frameworks, and early adoption of premium devices and novel therapeutics.

• •Asia-Pacific represents the fastest-growing regional market, led by China and India, driven by rising diabetes incidence in rapidly urbanizing populations, expanding healthcare infrastructure, and growing middle-class access to modern diabetes therapies
• •Europe accounts for approximately 20-25% of the global market, with strong adoption of advanced CGM systems and government-supported diabetes care programs across the UK, Germany, and France
• •The Middle East, Africa, and Latin America collectively represent smaller but fastest-growing regional shares, with improved screening programs and expanding generic and biosimilar access narrowing the global diabetes care gap

What are the recent trends and outlook?

The convergence of diabetes and obesity therapeutics is one of the most transformative trends reshaping the market, as GLP-1 therapies approved for diabetes are being widely adopted for weight management, dramatically expanding the addressable patient population and total market value. Digital health integration is accelerating, with smart insulin pens, AI-powered CGM algorithms, telehealth-enabled diabetes management platforms, and cloud-connected devices creating more personalized and automated care experiences.

• •Oral formulations of GLP-1 therapies and once-weekly injectable alternatives are in advanced development, promising to expand patient adherence and address the significant unmet need for oral diabetes treatments that match injectable efficacy
• •Biosimilar insulin competition is intensifying globally, particularly in European and emerging markets, which may compress pricing for established insulin products while accelerating volume-based access improvements
• •Device manufacturers are prioritizing miniaturization, improved accuracy, and lower cost to expand adoption in price-sensitive emerging markets, while integration with electronic health records and AI-driven decision support is becoming a key differentiation factor